Loading...
Loading...
LUMO| Name | Value |
|---|---|
| Revenues | 488.0K |
| Cost of Revenue | 2.0K |
| Gross Profit | 486.0K |
| Operating Expense | 8,309.0K |
| Operating I/L | -7,823.0K |
| Other Income/Expense | 272.0K |
| Interest Income | 70.0K |
| Pretax | -7,551.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -7,551.0K |
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapeutics for rare diseases. Their lead therapeutic candidate, LUM-201, is an oral growth hormone secretagogue ibutamoren currently in Phase 2 clinical trial for pediatric growth hormone deficiency and other rare endocrine disorders.
